Table 6.
In vitro activity of MRX-8 and other comparator agents against 80 of other non-fermentative bacteria (mg/L).
| Isolates | Antimicorbial agents | MIC (mg/liter) | R, % | S, % | ||
|---|---|---|---|---|---|---|
| Range | 50% | 90% | ||||
| Stenotrophomonas maltophilia (n = 30) | MRX-8 | 0.25->32 | 8 | >32 | – | – |
| Polymyxin B | 0.25->32 | 8 | 32 | – | – | |
| Colistin | 0.5->8 | 8 | >8 | – | – | |
| Amikacin | 4->64 | >64 | >64 | – | – | |
| Ceftazidime | 4->64 | 64 | >64 | 63.3 | 23.3 | |
| Ceftazidime-avibactam | 2->64 | 16 | 64 | – | – | |
| Cefoperazone-sulbactam | 8-64 | 32 | 64 | – | – | |
| Meropenem | >16->16 | >16 | >16 | – | – | |
| Levofloxacin | 0.125-16 | 2 | 8 | 23.3 | 63.3 | |
| Burkholderia cepacia (n = 30) | MRX-8 | 0.25->32 | >32 | >32 | – | – |
| Polymyxin B | 0.5->32 | >32 | >32 | – | – | |
| Colistin | 0.5->8 | >8 | >8 | – | – | |
| Amikacin | 1->64 | >64 | >64 | – | – | |
| Ceftazidime | 0.25-32 | 8 | 16 | 10 | 80 | |
| Ceftazidime-avibactam | 0.25-16 | 4 | 4 | – | – | |
| Cefoperazone-sulbactam | 2->64 | 64 | >64 | – | – | |
| Meropenem | ≤0.06-8 | 4 | 4 | 0 | 90 | |
| Levofloxacin | ≤0.06-16 | 2 | 4 | 10 | 83.3 | |
| Alcaligenes app. (n = 20) | MRX-8 | 0.06->32 | 1 | 4 | – | – |
| Polymyxin B | 0.25->32 | 2 | 4 | – | – | |
| Colistin | 0.25->8 | 2 | 4 | – | – | |
| Amikacin | 4->64 | >64 | >64 | 70 | 30 | |
| Ceftazidime | 1->64 | 8 | >64 | 30 | 60 | |
| Cefepime | 4->64 | 32 | >64 | – | – | |
| Ceftazidime-avibactam | 1->64 | 4 | 64 | 25 | 60 | |
| Cefoperazone-sulbactam | 1->64 | 8 | >64 | 25 | 70 | |
| Meropenem | 0.06->16 | 0.125 | >16 | 20 | 75 | |
| Ciprofloxacin | 1->64 | 4 | 64 | – | – | |
R, resistant; S, susceptible. All the intermediate data were not showed in table.